BCM
REVB icon

Bridgeway Capital Management’s Revelation Biosciences REVB Stock Holding History

Bridgeway Capital Management’s Portfolio REVB Stock Details REVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1
Closed -$135K – 1444
2022
Q2 		$135K Buy
+1
New +$148K ﹤0.01% 1169
2022
Q1 		– Hold
0
– – – 1294

Other funds holding REVB

Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
MFA
Mayflower Financial Advisors Boston, Massachusetts $1.16B AUM 24.36% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return

Bridgeway Capital Management's REVB Position: Q3 2022 in Review

Bridgeway Capital Management sold out of Revelation Biosciences (REVB) in Q3 2022, closing a stake of 1 share — an estimated $135K sold.

Bridgeway Capital Management first reported a position in REVB in Q2 2022 and held it in 1 quarter. The position peaked at $135K in Q2 2022. 2 funds tracked by Wall St. Rank hold REVB as of Q3 2022.

  • Bridgeway Capital Management reported no remaining Revelation Biosciences position as of Q3 2022 after selling out during the quarter.
  • Bridgeway Capital Management sold 1 Revelation Biosciences share in Q3 2022, an estimated $135K.
  • Bridgeway Capital Management first reported a position in Revelation Biosciences in Q2 2022 and held it in 1 quarter.
  • Bridgeway Capital Management's Revelation Biosciences position peaked at $135K in Q2 2022.
  • 2 funds tracked by Wall St. Rank held Revelation Biosciences as of Q3 2022.

Based on Bridgeway Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.